Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated  Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report.

d'Arienzo, Paolo D; MacDonald, Alan R; Patel, Virjen; Ma, Yuk T; Pihlak, Rille; Starling, Naureen

Publication

Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report.

Abstract

Multiple FGFR inhibitors have demonstrated significant activity in pretreated advanced FGFR2 fusion-positive intrahepatic cholangiocarcinoma. The irreversible pan-FGFR inhibitor futibatinib has the potential to overcome acquired resistance to ATP-competitive FGFR inhibitors in a subset of patients. We present a case of prolonged clinical benefit using FGFR inhibitors sequentially, initially an ATP-competitive inhibitor followed by futibatinib upon progression, for a total of 36 months of FGFR-targeting therapy. This case supports sequential FGFR-targeting therapies for FGFR2 fusion-positive cholangiocarcinoma, with futibatinib acting as rescue therapy after failure of ATP-competitive inhibitors.

Author

d'Arienzo, Paolo D
MacDonald, Alan R
Patel, Virjen
Ma, Yuk T
Pihlak, Rille
Starling, Naureen

Date

2024-06-13

Type

Article
Other

Subject

Oncology. Pathology.

Collections

UHB Oncology

Show all metadata

Citation

d'Arienzo PD, MacDonald AR, Patel V, Ma YT, Pihlak R, Starling N. Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report. Onco Targets Ther. 2024 Jun 13;17:489-496. doi: 10.2147/OTT.S434449.

Journal / Source Title

OncoTargets And Therapy

DOI

10.2147/OTT.S434449

URI

http://hdl.handle.net/20.500.14200/5160

PMID

38895132

Publisher

Dove Press

Publisher’s URL

https://www.ncbi.nlm.nih.gov/pmc/journals/1214/